COVID-19 News: NIAID Trial Tests Strategy to Augment Response to COVID-19 Vaccines in Transplant Recipients

Does temporarily reducing immunosuppressive medication safely allow for better antibody responses to vaccination?

Monday, January 31, 2022 NIAID Trial Tests Strategy to Augment Response to COVID-19 Vaccines in Transplant Recipients Colorized scanning electron micrograph of a cell (purple) infected with a variant strain of SARS-CoV-2 virus particles (pink), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID A new NIAID-funded clinical trial is testing whether temporarily reducing immunosuppressive medication taken during the days before and after an additional dose of an mRNA COVID-19 vaccine safely allows for better antibody responses to vaccination in kidney and liver transplant recipients. The study team is enrolling people for whom two to four doses of a COVID-19 mRNA vaccine did not elicit a detectable antibody response. The trial is called COVID Protection After Transplant‒Immunosuppression Reduction, or CPAT-ISR. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107